Assembly Biosciences to Present Data on ABI-H0731 at AASLD 2016 Liver Meeting
November 11 2016 - 8:00AM
Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage
biotechnology company advancing a new class of oral therapeutics
for the treatment of hepatitis B virus (HBV) infection and novel
oral biotherapeutics for disorders associated with the microbiome,
today announced it will present new data at The Liver Meeting®
2016, the Annual Meeting of the American Association for the Study
of Liver Diseases (AASLD), being held on November 11-15, 2016 in
Boston.
“This latest presentation shows that our proprietary core
protein allosteric modulators (CpAMs) have unique antiviral
properties, including the critical ability to stop the formation of
new cccDNA,” said Richard Colonno PhD, chief scientific officer of
Assembly. “This data presentation is especially timely, as earlier
this week we initiated the first Phase 1 trial of Assembly’s lead
CpAM candidate, ABI-H0731. We look forward to assessing the
potential for CpAMs to help change the treatment paradigm and
increase cure rates for HBV patients.”
Poster #1897:Blockage of HBV Virus Replication
and Inhibition of cccDNA Establishment by Core Protein Allosteric
Modifiers (CpAMs)
- November 14, 2016 from 12:00 PM to 1:30 PM
- Presented by: Richard Colonno, PhD, and Qi Huang, PhD, Director
of Biology
- Summary: Assembly has developed a proprietary series of CpAM
compounds that can both suppress viral replication and inhibit the
formation of cccDNA in HBV cell infection assays. In comparison,
nucleos(t)ide therapy, such as the the current HBV standard of care
drug entecavir, can efficiently block viral replication but has
only a modest impact on cccDNA levels.
Poster #1897 can be viewed at the events section at the
company’s website or at www.liverlearning.org.
About Assembly Biosciences Assembly
Biosciences, Inc. is a public biotechnology company developing
two innovative platform programs: an HBV program advancing a new
class of oral therapeutics for the treatment of hepatitis B virus
(HBV) infection and a microbiome program developing novel oral
biotherapeutics designed to address diseases associated with the
microbiome. Assembly‘s HBV program is advancing multiple drug
candidates with the aim of increasing cure rates in patients with
chronic HBV. The company’s microbiome program consists of a fully
integrated platform that includes a robust strain identification
and selection process, methods for strain isolation and growth
under current Good Manufacturing Practices and a patent-pending
delivery system, GEMICEL®, which allows for targeted oral delivery
of live biologic and conventional therapies to the lower
gastrointestinal tract. The lead program from this platform is in
development for the treatment of C. difficile infections. Assembly
is also developing additional microbiome product candidates. For
more information, visit assemblybio.com.
Forward-Looking StatementsThe information in
this press release contains estimates and other forward-looking
statements regarding future events, including statements about the
clinical and therapeutic potential of our HBV-cure program, timing
of the initiation of and availability of data from our ongoing and
planned clinical trials, and plans, strategies, and intentions
related to our programs. Certain forward looking statements may be
identified by reference to a future period or periods or by use of
forward-looking terminology such as “developing,” “potential,”
“projected,” “anticipated,” “positioned,” “strategy,” “should” or
“may.” Such forward-looking statements, which we intend to be
covered by the safe harbor provisions contained in Section 27A of
the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, are just predictions
and are subject to risks and uncertainties that could cause the
actual events or results to differ materially. These risks and
uncertainties include, among others: preclinical models may not be
representative of disease behavior in clinical studies; our ability
to retain necessary employees and to staff our operations
appropriately; the components, timing, cost and results of clinical
trials and other development activities involving our product
candidates; the unpredictability of the preclinical and clinical
development of our product candidates and of the duration and
results of regulatory review of those candidates by the FDA and
foreign regulatory authorities; our anticipated capital
expenditures, our estimates regarding our capital requirements, and
our need for future capital; and the possible impairment of, or
inability to obtain, intellectual property rights and the costs of
obtaining such rights from third parties. These and other potential
risks and uncertainties that could cause actual results to differ
from the results predicted are more fully detailed under the
heading “Risk Factors” in our Annual Report on Form 10-K for the
year ended December 31, 2015, and other reports filed with the
Securities and Exchange Commission. It is not possible for Assembly
management to predict all risks nor can Assembly assess the impact
of all factors on its business or the extent to which any factor,
or combination of factors, may cause actual results to differ
materially from those contained in any forward-looking statements
Assembly may make. In light of these risks, uncertainties and
assumptions, the forward-looking events and circumstances discussed
in this press release may not occur and actual results could differ
materially and adversely from those anticipated. Except as required
by law, we assume no obligation to update publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Contacts
Investors:
Assembly Biosciences, Inc.
Lauren Glaser
lglaser@assemblybio.com
Media:
Barbara Lindheim
barbara@assemblybio.com
212 584-2276
Assembly Biosciences (NASDAQ:ASMB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Assembly Biosciences (NASDAQ:ASMB)
Historical Stock Chart
From Sep 2023 to Sep 2024